Stocklytics Platform
Asset logo for symbol BIO
Bio-Rad Laboratories
BIO57
$277.16arrow_drop_down9.33%-$28.60
Asset logo for symbol BIO
BIO57

$277.16

arrow_drop_down9.33%

Income Statement (BIO)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
EBIT-$873.79M-$2.77B$503.35M$440.75M
EBITDA$58.40M$922.89M-$2.72B$551.15M$493.75M
gross Profit$342.00M$355.90M$355.71M$326.46M$365.90M
NET Income-$715.80M$653.17M-$2.16B$383.91M$349.70M
total Revenue$667.50M$649.72M$638.47M$610.82M$681.18M

Balance Sheet (BIO)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
cash Equivalents-----
net Debt-$486.90M$977.73M$985.39M$966.38M$1.00B
stockholders Equity$6.56B$7.48B$6.77B$9.05B$8.74B
total Assets$9.36B$10.60B$9.68B$12.60B$12.29B
total Debt$1.20M$1.38B$1.39B$1.39B$1.40B
total Liabilities$2.79B$3.11B$2.90B$3.55B$3.55B

Cash Flow (BIO)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$95.98M-$96.58M$638.00K-$200.62M-$26.59M
free Cash Flow$99.97M$55.36M$28.99M$38.80M$53.64M
investing Cash Flow-----$51.98M
operating Cash Flow$163.61M$97.64M$69.17M$81.04M$97.71M

Bio-Rad Laboratories (BIO) Financials

Bio-Rad Laboratories Inc. (BIO) is a leading global provider of life science research and clinical diagnostic products. The company offers a wide range of instruments, reagents, consumables, software, and services to support scientific discoveries, drug development, and diagnostics. With a strong focus on innovation and customer satisfaction, Bio-Rad has established itself as a trusted partner to researchers, healthcare professionals, and biopharmaceutical companies around the world.
The financial performance of Bio-Rad Laboratories Inc. reflects its strong position in the market. The income statement shows the company's revenue, expenses, and profitability over a specific period. Bio-Rad has consistently achieved solid gross profit margins, indicating its ability to generate revenue and control costs effectively. The net income from stockholders is another key metric, representing the profit available to the company's shareholders.
Bio-Rad Laboratories Inc. has also maintained a healthy balance sheet, as shown in its financial statements. The total assets value represents the company's investments in various assets, including cash equivalents, inventory, property, and equipment. The balance sheet also includes the total liabilities, which are the obligations that Bio-Rad owes to its creditors and other stakeholders.
One important aspect of Bio-Rad's financials is its cash flow. The cash flow statement shows how cash is generated and used by the company during a specific period. Operating cash flow represents the cash generated from the company's core operations, such as selling products and providing services. Investing cash flow includes cash used for acquiring or selling assets, while financing cash flow involves cash transactions related to raising funds or returning capital to shareholders.
Bio-Rad Laboratories Inc. has demonstrated its strong financial position through its ability to generate positive free cash flow. Free cash flow is an essential metric for evaluating a company's financial health as it measures the cash generated after accounting for capital expenditures and working capital requirements. A positive free cash flow indicates that the company has sufficient cash to invest in growth opportunities, repay debts, and return value to shareholders.
Overall, Bio-Rad Laboratories Inc. maintains a solid financial standing, supported by its innovative products, strong customer relationships, and global presence. The company's financials highlight its ability to generate revenue, control costs, and generate positive cash flow, making it a reliable and attractive investment for stakeholders.
add Bio-Rad Laboratories  to watchlist

Keep an eye on Bio-Rad Laboratories

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level